Treatment Guidelines: Schizophrenia

American Psychiatric Association (APA)

• Practice guideline for the treatment of patients with schizophrenia (2020)

British Association for Psychopharmacology (BAP)

• Evidence-based guidelines for the pharmacological treatment of schizophrenia (2020)

Canadian Psychiatric Association

• Guidelines for pharmacotherapy of schizophrenia in adults (2017)

European Psychiatric Association (EPA)

• Guidance on treatment of cognitive impairment in schizophrenia (2022)

National Institute for Health and Care Excellence (NICE)

• Psychosis and schizophrenia in adults: prevention and management (2014)
• Psychosis and schizophrenia in children and young people: recognition and management (2013; updated 2016)

Royal Australian and New Zealand College of Psychiatrists (RANZCP)

• Clinical practice guidelines for the management of schizophrenia and related disorders (2016)

World Federation of Societies of Biological Psychiatry (WFSBP)

• Part 3: Management of special circumstances in the treatment of schizophrenia: depression, suicidality, substance use disorders and pregnancy and lactation (2015)
• Part 2: Long-term treatment of schizophrenia and management of antipsychotic-induced side effects (2013)
• Part 1: Acute treatment of schizophrenia and management of treatment resistance (2012)

VA/DoD Clinical Practice Guidelines

• Management of First-Episode Psychosis and Schizophrenia (2023)

Reviewer 1: Leah Rickert, PharmD, BCPP
Reviewer 2: Austin Smith, PharmD, BCPP
2024-2025 AAPP Resident and New Practitioner Committee